Company research
LEMAITRE VASCULAR INC
CIK 1158895Updated Sep 24, 2026
SecurityLMAT · NASDAQ · equity
LMAT price & chart
Loading TradingView…
NASDAQ:LMAT on TradingView ↗About the company
LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. LeMaitre is a registered trademark of LeMaitre Vascular, Inc. This press release may include other trademarks and trade names of the Company.
In the news
LeMaitre to Participate at Upcoming Investor Conferences in September ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 615,690,000Source | 551,817,000Source | 346,778,000Source | 310,476,000Source |
| Property, Plant and Equipment, NetUSD | 26,997,000Source | 24,800,000Source | 21,754,000Source | 17,901,000Source |
| GoodwillUSD | 65,945,000Source | 65,945,000Source | 65,945,000Source | 65,945,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 33,089,000Source | 35,819,000Source | 41,711,000Source | 46,527,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 28,244,000Source | 25,610,000Source | 24,269,000Source | 19,134,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 33,610,000Source | 30,063,000Source | 25,064,000Source | 22,040,000Source |
| Assets, CurrentUSD | 468,232,000Source | 402,192,000Source | 194,598,000Source | 161,733,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,080,000Source | 7,480,000Source | 6,380,000Source | 6,731,000Source |
| Operating Lease, Right-of-Use AssetUSD | 15,762,000Source | 16,768,000Source | 18,027,000Source | 15,634,000Source |
| Other Assets, NoncurrentUSD | 4,906,000Source | 4,868,000Source | 3,740,000Source | 991,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 222,174,000Source | 214,527,000Source | 48,878,000Source | 42,275,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 244,000Source | 242,000Source | 239,000Source | 237,000Source |
| Retained Earnings (Accumulated Deficit)USD | 184,715,000Source | 145,090,000Source | 115,430,000Source | 97,773,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -2,411,000Source | -6,184,000Source | -4,625,000Source | -6,031,000Source |
| Stockholders' Equity Attributable to ParentUSD | 393,516,000Source | 337,290,000Source | 297,900,000Source | 268,201,000Source |
| Additional Paid in Capital, Common StockUSD | 228,407,000Source | 213,760,000Source | 200,755,000Source | 189,268,000Source |
| Liabilities and EquityUSD | 615,690,000Source | 551,817,000Source | 346,778,000Source | 310,476,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 36,323,000Source | 30,607,000Source | 29,879,000Source | 25,329,000Source |
| Operating Lease, Liability, CurrentUSD | 2,944,000Source | 2,681,000Source | 2,471,000Source | 1,886,000Source |
| Accounts Payable, CurrentUSD | 3,646,000Source | 1,761,000Source | 3,734,000Source | 2,903,000Source |
| Operating Lease, Liability, NoncurrentUSD | 14,003,000Source | 15,232,000Source | 16,624,000Source | 14,710,000Source |
| Deferred Income Tax Liabilities, NetUSD | 1,735,000Source | 85,000Source | 107,000Source | 69,000Source |
| Other Liabilities, NoncurrentUSD | 1,468,000Source | 831,000Source | 2,268,000Source | 2,167,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 29,411,000Source | 24,732,000Source | 23,650,000Source | 19,967,000Source |
| AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD | — | — | 1,200,000Source | 1,800,000Source |
| Deferred Tax Liabilities, NetUSD | 976,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 10,418,000Source | 9,670,000Source | 9,515,000Source | 9,433,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 7,826,000Source | 6,568,000Source | 5,319,000Source | 4,173,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 2,947,000Source | 6,418,000Source | 3,135,000Source | 3,533,000Source |
| Deferred Income Tax Expense (Benefit)USD | 2,312,000Source | -451,000Source | 783,000Source | -182,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 81,251,000Source | 44,124,000Source | 36,751,000Source | 25,378,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 1,899,000Source | 0Source | 899,000Source | 0Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -64,941,000Source | -200,120,000Source | -24,715,000Source | -10,371,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 1,821,000Source | 1,719,000Source | 853,000Source | 642,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -14,540,000Source | 158,102,000Source | -7,131,000Source | -9,234,000Source |
| Payments of Ordinary Dividends, Common StockUSD | 18,109,000Source | 14,378,000Source | 12,448,000Source | 10,988,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 2,634,000Source | 1,341,000Source | 5,135,000Source | 5,279,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 13,439,000Source | 12,837,000Source | 7,549,000Source | 8,343,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 7,826,000Source | 6,568,000Source | 5,319,000Source | 4,173,000Source |
| Amortization of Debt Issuance CostsUSD | 873,000Source | — | — | — |
| Amortization of Intangible AssetsUSD | 5,644,000Source | 5,785,000Source | 6,092,000Source | 6,183,000Source |
| Capitalized Computer Software, AmortizationUSD | 546,000Source | — | — | — |
| DepreciationUSD | 4,773,000Source | 3,823,000Source | 3,423,000Source | 3,250,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | 500,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | 176,000Source | -362,000Source | 705,000Source | 315,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | 115,000Source |
| Gain (Loss) on Disposition of BusinessUSD | 0Source | 0Source | -485,000Source | -1,954,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | -95,000Source |
| General and Administrative ExpenseUSD | 42,024,000Source | 36,258,000Source | 31,832,000Source | 28,745,000Source |
| GoodwillUSD | 65,945,000Source | 65,945,000Source | 65,945,000Source | 65,945,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 17,450,000Source | 12,837,000Source | 9,370,000Source | 6,854,000Source |
| Inventory Write-downUSD | 2,661,000Source | 3,092,000Source | 2,237,000Source | 2,572,000Source |
| Investment Income, InterestUSD | 13,094,000Source | 4,949,000Source | 3,077,000Source | 986,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | 1,000,000Source | 1,200,000Source | 1,800,000Source |
| Net Income (Loss) Attributable to ParentUSD | 57,734,000Source | 44,038,000Source | 30,105,000Source | 20,636,000Source |
| Operating ExpensesUSD | 110,627,000Source | 98,645,000Source | 90,337,000Source | 78,067,000Source |
| Other Nonoperating Income (Expense)USD | -638,000Source | -125,000Source | -314,000Source | -325,000Source |
| Payments of Financing CostsUSD | — | — | — | 0Source |
| Proceeds from Issuance of Common StockUSD | — | 6,440,000Source | 6,170,000Source | 3,466,000Source |
| Proceeds from Stock Options ExercisedUSD | 6,823,000Source | 6,400,000Source | 6,200,000Source | 3,500,000Source |
| Restructuring CostsUSD | 0Source | 0Source | 485,000Source | 3,107,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 249,602,000Source | 219,863,000Source | 193,484,000Source | 161,651,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | -535,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 249,602,000Source | 219,863,000Source | 193,484,000Source | 161,651,000Source |
| Cost of RevenueUSD | 71,063,000Source | 68,962,000Source | 66,435,000Source | 56,755,000Source |
| Operating Income (Loss)USD | 67,912,000Source | 52,256,000Source | 36,712,000Source | 26,829,000Source |
| Other Nonoperating Income (Expense)USD | -638,000Source | -125,000Source | -314,000Source | -325,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 75,184,000Source | 56,875,000Source | 39,475,000Source | 27,490,000Source |
| Income Tax Expense (Benefit)USD | 17,450,000Source | 12,837,000Source | 9,370,000Source | 6,854,000Source |
| Net Income (Loss) Attributable to ParentUSD | 57,734,000Source | 44,038,000Source | 30,105,000Source | 20,636,000Source |
| Earnings Per Share, BasicUSD per share | 2.55Source | 1.96Source | 1.36Source | 0.94Source |
| Earnings Per Share, DilutedUSD per share | 2.52Source | 1.93Source | 1.34Source | 0.93Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 22,638,000Source | 22,452,000Source | 22,217,000Source | 21,975,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 22,929,000Source | 22,779,000Source | 22,423,000Source | 22,171,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 5,644,000Source | 5,785,000Source | 6,092,000Source | 6,183,000Source |
| Capitalized Computer Software, AmortizationUSD | 546,000Source | — | — | — |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 0.8Source | 0.64Source | 0.56Source | 0.5Source |
| Current Income Tax Expense (Benefit)USD | 15,138,000Source | 13,288,000Source | 8,587,000Source | 7,036,000Source |
| General and Administrative ExpenseUSD | 42,024,000Source | 36,258,000Source | 31,832,000Source | 28,745,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | 0Source |
| Gross ProfitUSD | 178,539,000Source | 150,901,000Source | 127,049,000Source | 104,896,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 75,030,000Source | 52,829,000Source | 37,356,000Source | 26,274,000Source |
| Interest ExpenseUSD | 5,184,000Source | 205,000Source | 0Source | 0Source |
| Investment Income, InterestUSD | 13,094,000Source | 4,949,000Source | 3,077,000Source | 986,000Source |
| Operating ExpensesUSD | 110,627,000Source | 98,645,000Source | 90,337,000Source | 78,067,000Source |
| Research and Development ExpenseUSD | 14,139,000Source | 15,650,000Source | 16,966,000Source | 13,294,000Source |
| Restructuring CostsUSD | 0Source | 0Source | 485,000Source | 3,107,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 249,602,000Source | 219,863,000Source | 193,484,000Source | 161,651,000Source |
| Selling and Marketing ExpenseUSD | 54,464,000Source | 46,737,000Source | 41,054,000Source | 32,921,000Source |
Filing attachments
d320964dex991.htm · 8-K · 2026-08-04
EX-99.1 2 d320964dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 LeMaitre Q2 2026 Financial Results BURLINGTON, MA, August 4, 2026 - LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance. Q2 2026: Sales $70.4mm, +10% (+10% organic) vs. Q2 2025 Gross margin 72.1% (+210 bps) Op. income $20.4mm (+26%) Op. margin 29% EPS $0.74 (+23%) Cash up…
Read attachment ↗d94324dex991.htm · 8-K · 2026-05-05
EX-99.1 2 d94324dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 LeMaitre Q1 2026 Financial Results BURLINGTON, MA, May 5, 2026 - LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance. Q1 2026: Sales $66.6mm, +11% (+10% organic) vs. Q1 2025 Gross margin 72.7% (+350 bps) Op. income $17.8mm (+41%) Op. margin 27% EPS $0.68 (+42%) Cash up $8.…
Read attachment ↗d23187dex991.htm · 8-K · 2026-02-25
EX-99.1 2 d23187dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 LeMaitre Q4 2025 Financial Results BURLINGTON, MA, February 25, 2026 - LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0.25/share (+25%), and provided guidance. Q4 2025: Sales $64.5mm, +16% (+15% organic) vs. Q4 2024 Gross margin 71.7% (+240 bps) Op. income $18.8mm (+47%) Op. margin 29% Diluted EPS $0.68 …
Read attachment ↗d35939dex991.htm · 8-K · 2025-11-06
EX-99.1 2 d35939dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 LeMaitre Q3 2025 Financial Results BURLINGTON, MA, November 6, 2025 - LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q3 2025 results include a non-recurring benefit from the Employee Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-…
Read attachment ↗